Share on StockTwits
 

Celgene Corp. (NASDAQ:CELG)‘s stock had its “buy” rating reiterated by stock analysts at TheStreet in a report issued on Friday, AR Network reports.

The analysts wrote, “Celgene Corporation (CELG) has been reiterated by TheStreet Ratings as a buy with a ratings score of A-. The company’s strengths can be seen in multiple areas, such as its robust revenue growth, expanding profit margins, largely solid financial position with reasonable debt levels by most measures, solid stock price performance and notable return on equity. We feel these strengths outweigh the fact that the company has had sub par growth in net income.”

Celgene Corp. (NASDAQ:CELG) opened at 171.44 on Friday. Celgene Corp. has a 52-week low of $81.33 and a 52-week high of $173.80. The stock has a 50-day moving average of $163.3 and a 200-day moving average of $147.0. The company has a market cap of $70.645 billion and a price-to-earnings ratio of 49.51.

Celgene Corp. (NASDAQ:CELG) last released its earnings data on Thursday, October 24th. The company reported $1.56 EPS for the quarter, beating the Thomson Reuters consensus estimate of $1.54 by $0.02. The company had revenue of $1.67 billion for the quarter, compared to the consensus estimate of $1.64 billion. During the same quarter in the previous year, the company posted $1.29 earnings per share. The company’s revenue for the quarter was up 18.0% on a year-over-year basis.

CELG has been the subject of a number of other recent research reports. Analysts at Bank of America Corp. raised their price target on shares of Celgene Corp. to $196.00 in a research note to investors on Thursday, December 19th. They now have a “buy” rating on the stock. Separately, analysts at Credit Suisse upgraded shares of Celgene Corp. from a “neutral” rating to an “outperform” rating in a research note to investors on Tuesday, December 10th. They now have a $210.00 price target on the stock, up previously from $165.00. Finally, analysts at Citigroup Inc. reiterated a “buy” rating on shares of Celgene Corp. in a research note to investors on Friday, December 6th. They now have a $204.00 price target on the stock, up previously from $182.00. Three research analysts have rated the stock with a hold rating and twenty-two have given a buy rating to the company. The stock currently has an average rating of “Buy” and a consensus price target of $164.08.

In other Celgene Corp. news, Insider Lawrence Stein sold 12,062 shares of the stock in a transaction that occurred on Monday, December 23rd. The stock was sold at an average price of $168.19, for a total transaction of $2,028,707.78. Following the sale, the insider now directly owns 50 shares in the company, valued at approximately $8,410. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link.

Celgene Corporation is a global biopharmaceutical company engaged in the discovery, development and commercialization of therapies designed to treat cancer and immune-inflammatory related diseases.

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.